Bibliothèque de L'IMIST/CNRST

Includes bibliographical references and indexes.

Heart rate: a risk factor for cardiac diseases and outcomes? Pathophysiology of cardiac diseases and the potential role of heart rate slowing / Lanza, G.A., Fox, K., Crea, F. -- IF current inhibition: cellular basis and physiology / Mangoni, M.E., Marger, L., Nargeot, J. -- Heart rate reduction by pharmacological IF current inhibition / Cargnoni, A. [and others] -- Clinical perspectives of heart rate slowing for coronary event reduction and heart failure / Danchin, N., Kadri, Z. -- Clinical effect of 'pure' heart rate slowing with a prototype IF current inhibitor: placebo-controlled experience with ivabradine / Borer, J.S. -- Heart rate slowing versus other pharmacological antianginal strategies. Results of comparative studies / Diaz, A., Tardif, J.-C. -- Novel IF current inhibitor ivabradine: safety considerations / Savelieva, I., Camm, A.J. -- Heart rate slowing for myocardial dysfunction/heart failure. Rationale and preclinical studies / Mulder, P., Thuillez, C. -- Future directions: what data do we need? / Tendera, M.

This book unfolds the history of the discovery of the transmembrane channel which is responsible for the 'funny' or If current, the primary modulator of heart rate. Inhibition of this current leads to slowing of the heart rate, which is an important component of the successful management of angina pectoris. Recently, Ivabradine, a specific and selective inhibitor of the If current, has been developed as an antianginal agent which has been shown to be at least as effective as both beta-blockers and calcium channel blockers for the treatment of angina. The development, efficacy and complications.